Jacque Sokolov expects artificial intelligence to transform healthcare, beginning with administrative areas such as scribing and electronic health records. He says practitioners are also beginning to see its effects.
“Physicians are already using AI to facilitate their workflow, depending upon what type of medicine they’re practicing,” says Sokolov, who is chairman and CEO of SSB, a holding company that serves as his family office. “The radiology area is dramatically impacted positively. We’re not replacing radiologists — we’re just basically having radiologists read 20-30% more studies than they otherwise would, more accurately.”
This does not mean, however, that every new company with an AI-enabled medical product will succeed.
Sokolov, who has been investing in transformative technologies for decades, says it is critical to consider not only the technology itself, but also its path to overcoming legal and regulatory obstacles and being adopted by clinics and hospitals.
Sokolov cites Artrya, an Australian AI-enabled imaging company SSB has invested in, as an example both of the promise of AI in medicine and of the complex evaluation needed before investing.
Artrya’s technology looks at the characterization of plaque and the narrowing of coronary arteries using non-invasive technology called CCTA, or coronary computed tomography angiography scans.
“It uses AI-enabled imaging enhancement to look at things we could never even have seen before, which will change the whole nature of predictive cardiology in terms of major acute coronary events,” Sokolov says.
The company’s technology generates reports within minutes of a scan being completed and can identify narrowing of the coronary arteries without cardiac catheterization. It can also identify the type of plaque that is obstructing the arteries and determine whether the plaque is inflamed. This allows doctors to “predict cardiac disease much more accurately and much more effectively,” Sokolov says.
“Our firm thought this AI-enabled technology would be transformative, and we made a significant investment five years ago,” Sokolov says. “We were early investors in Artrya, when it was about a $35 million company. It’s close to $1 billion today.”
Evaluating innovative companies using four filters
Before SSB made that investment, the technology had to pass through the four filters Sokolov uses to assess all healthcare investments.
“An investment is only as good as the ultimate revenue stream that the business is able to create,” Sokolov says. “You need to have all these different filters all aligned so that you ultimately have a sustainable business that has an ongoing revenue stream.”
Clinical filter: Does the transformative technology create a better clinical solution, whether diagnostic, therapeutic, or some other type?
“In this case, it’s diagnostic imaging technology, and the answer is that AI clearly does create a better solution for this particular area,” Sokolov says.
Regulatory and legal filter: Does the technology have a reasonable regulatory or legal pathway to actually get into the marketplace?
Hospitals and clinics use CPT codes to report services to insurance companies for billing. And for a technology to have a CPT code, it needs FDA approval.
“Artrya has successfully navigated several FDA approvals, and is actually in the marketplace, commercially available, because of that FDA success,” Sokolov says. This means providers who use the technology can bill insurance companies using a CPT code.
Business filter: Who will pay for this technology? Can they use a CPT code to get reimbursed? If not, how long is the pathway to making this possible?
In Artrya’s case, CPT codes for AI-enabled imaging in cardiology already existed.
“The codes that are being used for Artrya and other AI-enabled CCTA companies are already well-established, so the business model, which has taken probably a decade to get to, is already in place,” Sokolov says, noting that this illustrates the value of being a fast follower, as opposed to being the initial pioneer trying to get reimbursement codes established.
Adoption filter: Do the doctors, health systems, and/or health plans see value in changing what they do today and actually adopting this new transformative technology?
In Artrya’s case, the answer is yes, Sokolov says.
“The doctors certainly do, because they can read these scans in 5 to 8 minutes, as opposed to 45 minutes,” Sokolov says. “The health systems do, because it can open up the CT scanners to more volume, because it doesn’t take so long to do each of the scans. And the insurance companies, depending upon how well they understand the predictability and impact on the clinical model, can identify disease earlier and treat it more effectively at a lower cost.”
Looking ahead
Although Sokolov expects AI to transform medicine, that doesn’t mean it will replace large numbers of medical workers.
“Healthcare providers — doctors, advanced practitioners, nurses, pharmacists, etc. — I think are very safe in their jobs. I think AI will become an integral tool to make them better at what they do,” Sokolov says. “There’s still no substitute for actually listening to the patient.”
He is optimistic that Artrya’s targeted approach will turn AI-enabled CCTA into one of the success stories.
“It is a very discrete point solution, not an overall AI workflow solution that has 20 different elements to it,” Sokolov says. “That doesn’t mean other AI solutions won’t be successful as well. At the end of the day, people are trying to figure out how to commercialize, monetize, capitalize on AI technology and healthcare. Certainly, in AI-enabled imaging, there’s a clear pathway to that commercialization and scaling.”
Still, he has learned through decades of investing that even clear pathways can hold surprises.
“There are always unpredictable twists and turns,” Sokolov says. “Sometimes companies you think are going to be very, very successful take much longer than you think. Sometimes they grow much bigger than you anticipate. And quite frankly, sometimes they don’t take off. The key across all these different investments is that you basically have to be able to look around the corners — but not drive off the road.”

